On Nov. 6, 2026, aTyr Pharma filed a prospectus supplement allowing it to sell up to $79,994,251 of common stock through an at-the-market (ATM) program.
The sales would take place from time to time under the company’s existing Open Market Sale Agreement with Jefferies LLC, originally signed in 2022 and amended in 2024. The filing does not mean the full amount will necessarily be sold.
The prospectus says Jefferies’ commission is 3% of gross proceeds. aTyr expects to use net proceeds mainly for general corporate purposes, including research and clinical development.
At the assumed share price of $6.03—the closing price cited for Nov. 5—the maximum amount would represent about 13.3 million shares. Actual share sales and any resulting dilution would depend on how much aTyr sells and at what prices.
Sources:
sec-gov-archives-edgar-data-0001339970-000133997026000083-atm-prosupp-nov-2026-htm
aTyr Pharma files to offer up to $80M in common stock via ATM program
sec-gov-archives-edgar-data-0001339970-000133997026000076-atyr-ex99-1-htm
aTyr Pharma plans up to $80M common stock offering
aTyr Pharma News Today | ATYR Stock News - Investing.com AU
aTyr Pharma files to offer up to $80M in common stock via ...
aTyr Pharma may sell up to $80M in stock offering
Life Technologies Stock Price Today | NASDAQ: ATYR Live
aTyr Pharma, Inc. - 8-K Other Events | MEDIUM Risk | Filed ...
ATyr Pharma Files ~$80M At-The-Market Offering To Sell Common Stock Through Jefferies
ATYR Stock Real Time Quote - Atyr Pharma Inc Stock Price with Chart